Skip to main content

Health condition · Clinically reviewed

Brain AVM, Spetzler-Martin grading, the ARUBA debate and modern treatment.

A congenital tangle of vessels that shunts blood directly from arteries to veins. Most are picked up in the 20s to 40s, often after a bleed, a first seizure or an incidental scan. Treatment choice is careful, multidisciplinary and shared.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, NHS neurosciences standards and peer-reviewed neurovascular literature you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK neurovascular practice including post-ARUBA decision-making, Spetzler-Martin grading and multimodal treatment.

Key facts

Brain AVM at a glance.

The essentials, in plain English: what it is, how it presents, how it is graded and how it is treated in the UK today.

  • What it is

    A brain AVM is a congenital tangle of abnormal blood vessels where arteries shunt directly into veins with no normal capillary bed in between.

  • How common

    Incidence is around 1 in 100,000 per year. Most present between the ages of 20 and 40, though some are picked up incidentally at any age.

  • How it presents

    Roughly half present with intracerebral haemorrhage, a quarter with seizure, around 15% with headache, and 10% with a focal neurological deficit.

  • Annual bleed risk

    A previously unruptured AVM carries roughly a 2 to 4% annual risk of rupture. That risk is cumulative over a lifetime.

  • How it is graded

    The Spetzler-Martin scale (I to V) combines size, eloquence of the surrounding brain and pattern of venous drainage to predict surgical risk.

  • How it is treated

    Options include microsurgery, stereotactic radiosurgery, endovascular embolisation, combined multimodal care and, for selected unruptured AVMs, observation.

Why this guide matters

A shared decision, not a one-size-fits-all fix.

Brain AVM care is one of the most nuanced areas of neurosurgery. The three points below shape everything else on this page.

  • Grading drives the plan

    The Spetzler-Martin scale (I to V) captures size, eloquence and venous drainage. It is the single most useful predictor of surgical risk.

  • ARUBA changed the conversation

    For unruptured AVMs, medical management may be non-inferior to intervention. Every case is now weighed carefully with the neurovascular MDT.

  • Multimodal care is the norm

    Microsurgery, radiosurgery and embolisation are increasingly combined. The right sequence depends on nidus size, location and anatomy.

How the diagnosis is made

From first scan to a defined nidus and grade.

The steps a UK neurovascular team will normally follow, in order, so you know what to expect and why.

  1. 01

    Assessing

    Clinical assessment

    A detailed neurological history and examination. Was there a sudden severe headache, a first seizure, a focal deficit, or an incidental scan finding?

  2. 02

    Assessing

    CT and CTA in acute bleeding

    For a suspected intracerebral haemorrhage, urgent CT confirms the bleed and CT angiography looks for an underlying vascular malformation.

  3. 03

    Assessing

    MRI and MRA of brain (and spine)

    MRI defines the nidus, surrounding brain and any prior haemorrhage. MRA maps arterial supply and venous drainage. Spinal imaging is added when hereditary conditions are suspected.

  4. 04

    Confirming

    Digital subtraction angiography

    DSA remains the gold standard: it details arterial feeders, venous drainage, associated aneurysms, fistulous components, flow characteristics and provides the data needed for Spetzler-Martin grading.

  5. 05

    Confirming

    Functional MRI and DTI

    Used to map eloquent cortex (speech, motor, vision) and white-matter tracts near the nidus, so surgery and radiosurgery can spare critical function.

  6. 06

    Preparing

    Neuropsychology baseline

    Formal cognitive testing before treatment gives a benchmark for recovery and helps plan rehabilitation.

  7. 07

    Preparing

    Genetic screening if HHT features

    When features suggest hereditary haemorrhagic telangiectasia (recurrent epistaxis, telangiectasia, family history), genetic testing and cascade screening of relatives are offered.

Typical timeline: from first scan to a defined treatment plan within a few weeks at a specialist neurovascular centre.

Symptoms

How a brain AVM actually announces itself.

The classic mix is haemorrhage, seizure, headache or focal deficit, and an increasing number are found incidentally on MRI done for other reasons.

  • Intracerebral haemorrhage

    The most common first presentation (around 50%). Sudden severe headache, vomiting, reduced consciousness or focal deficit. Needs emergency assessment.

  • First seizure

    Around a quarter present with seizures, focal or generalised. A first adult seizure always warrants brain imaging.

  • Headache

    Around 15% present with chronic or unusual headaches. Pattern change, thunderclap onset or new focal features are the concerning signals.

  • Focal neurological deficit

    Around 10% present with weakness, sensory change, visual disturbance, speech difficulty or coordination problems related to nidus location.

  • Pulsatile tinnitus or bruit

    A rushing noise in time with the pulse, sometimes audible on auscultation, can point to a high-flow shunt.

  • Cognitive or behavioural change

    Slowly progressive cognitive change from vascular steal or prior small bleeds. Often subtle and easy to attribute to other causes.

  • Incidental discovery

    Increasingly common as MRI is used for unrelated symptoms. An incidental AVM still needs specialist neurovascular assessment.

  • Red flag - acute rupture

    Sudden severe headache, collapse, seizure or focal deficit needs a 999 call and emergency stroke or neurosurgical care.

Treatment

How brain AVM is treated in the UK.

Care is centralised in specialist neurovascular centres (including Queen Square, King's, Cambridge, Oxford, Sheffield, Newcastle, Bristol, Manchester, Edinburgh and Glasgow) and delivered by a multidisciplinary team.

  • Microsurgical resection

    Best long-term cure for accessible low-grade AVMs (Spetzler-Martin I and II). Immediate obliteration with high success at specialist neurovascular centres.

  • Stereotactic radiosurgery (SRS)

    Gamma Knife, CyberKnife, LINAC or proton beam. Best suited to small, deep or eloquent-location AVMs. Obliteration takes 2 to 3 years and reaches 70 to 90% for lesions under 3cm.

  • Endovascular embolisation

    Onyx, n-BCA glue or coils delivered through a microcatheter. Used as an adjunct to surgery or SRS, and sometimes curative for small or fistulous lesions.

  • Combined multimodal care

    Large or complex AVMs are often staged: embolisation followed by surgery, or embolisation followed by radiosurgery, planned by the neurovascular MDT.

  • Observation and surveillance

    For selected unruptured, low-risk AVMs after shared decision-making (post-ARUBA), with serial MRI and careful counselling on annual bleed risk.

  • Treatment after rupture

    A ruptured AVM is usually treated within 3 to 6 months, once acute recovery allows, to reduce the risk of re-rupture.

  • Medical and anti-epileptic therapy

    Anti-epileptic drugs (levetiracetam, lamotrigine) control seizures. Bevacizumab is emerging for HHT-related AVMs, reducing epistaxis and high-output cardiac failure.

  • Rehabilitation

    After haemorrhage or treatment, structured physical, cognitive, speech, occupational and psychological rehabilitation supports the best possible recovery.

Key controversy

The ARUBA trial and unruptured AVMs.

The 2014 ARUBA trial reported that, for unruptured brain AVMs, medical management was non-inferior to intervention over roughly five years. Methodological concerns, patient-selection issues and short follow-up mean the debate is ongoing. In practice, every unruptured AVM is discussed by the neurovascular MDT and the decision is shared with the patient, weighing anatomy, age, symptoms, occupation and personal preference.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, specialist society standards and landmark neurovascular trials, current at the time of last review.

Key references

Guidelines and evidence we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your neurovascular team knows your imaging, history and priorities and can tell you which parts apply to you. If in doubt, get seen.

  • NICE guidance on stroke, transient ischaemic attack and neurovascular disease.

  • Mohr JP et al. ARUBA trial. The Lancet, 2014, and subsequent long-term follow-up analyses.

  • Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. Journal of Neurosurgery.

  • Spetzler RF, Ponce FA. A 3-tier classification of cerebral arteriovenous malformations. Journal of Neurosurgery.

  • British Society of Neuroradiologists and Society of British Neurological Surgeons neurovascular standards.

  • NHS England service specification for neurosciences and specialised neurovascular care.

Red flags

When a brain AVM needs urgent attention.

Some symptoms need a 999 call. Others need a same-day GP or specialist review. Do not sit on any of these.

  • Sudden severe (thunderclap) headache

    A headache that peaks within seconds and is the worst of your life needs a 999 call. It can signal AVM rupture or subarachnoid haemorrhage.

  • First seizure in an adult

    Any first adult seizure warrants brain imaging and neurology review, even if recovery is quick.

  • New focal neurological deficit

    Sudden weakness, numbness, speech difficulty or visual loss should be treated as a stroke until proven otherwise. Call 999.

  • Reduced consciousness or collapse

    Drowsiness, confusion or loss of consciousness after headache or seizure is an emergency.

  • Rapidly worsening headache

    A headache that steadily worsens over hours, with vomiting or visual change, needs urgent assessment.

  • Pregnancy and known AVM

    Pregnancy and delivery planning should involve the neurovascular MDT and obstetrics, given altered haemodynamics and bleeding risk.

  • HHT features

    Recurrent nosebleeds, mucocutaneous telangiectasia and family history should prompt screening for hereditary haemorrhagic telangiectasia and cerebral or spinal AVMs.

  • Post-treatment new symptoms

    New headache, seizure or deficit after surgery, radiosurgery or embolisation needs prompt review by the treating neurovascular team.

  • Anticoagulation and known AVM

    The decision to start or continue anticoagulation or antiplatelet therapy must involve the neurovascular team, as it affects bleeding risk.

Living with it

A serious diagnosis, with a considered path forward.

Four things that make the biggest difference: the right team, the right conversation, sensible day-to-day choices and knowing where to turn for support.

A quiet reminder

You have time to ask questions.

Outside acute rupture, most brain AVM decisions do not have to be made this week. Take the time to understand your grade, your options and your team.

  1. 01 Team

    A neurovascular MDT should own your care

    Neurosurgery, interventional neuroradiology, neurology, radiation oncology and specialist rehabilitation together weigh options and monitor progress.

  2. 02 Decision

    Understand the ARUBA debate

    For unruptured AVMs, the ARUBA trial suggested medical management may be non-inferior to intervention. Methodology and follow-up remain debated. Talk it through carefully.

  3. 03 Lifestyle

    Sensible day-to-day choices

    Control blood pressure, avoid smoking, moderate alcohol, and discuss contact sports, altitude and diving with your team before making changes.

  4. 04 Support

    You are not on your own

    The Brain and Spine Foundation, Different Strokes and Aneurysm Support UK offer information, peer support and rehabilitation guidance for patients and families.

Frequently asked

Everything we get asked about brain AVM.

Quick answers on bleeding risk, grading, ARUBA, treatment options and what happens after a rupture.

  • What is a brain AVM?

    A brain arteriovenous malformation is a congenital tangle of abnormal blood vessels in which arteries connect directly to veins without a normal capillary bed. The high-pressure shunt can bleed, cause seizures, headache or focal deficits, or be found incidentally on brain imaging.

  • How likely is a brain AVM to bleed?

    An unruptured brain AVM carries roughly a 2 to 4% annual risk of haemorrhage. Because the risk is cumulative over a lifetime, treatment is often considered in younger patients, particularly if features on angiography suggest higher-risk anatomy such as associated aneurysms or deep venous drainage.

  • What is Spetzler-Martin grading?

    It is a five-tier scale that predicts the risk of open surgery. It combines size (under 3cm, 3 to 6cm, over 6cm), whether the AVM sits in eloquent brain (speech, motor, vision, brainstem, cerebellar nuclei), and whether venous drainage is deep. The Spetzler-Ponce system simplifies these into three classes (A, B and C) for shared decision-making.

  • What did the ARUBA trial say?

    The 2014 ARUBA trial found that, for unruptured brain AVMs, medical management was non-inferior to intervention over roughly five years of follow-up. The trial has faced criticism on methodology, patient selection and short follow-up, so decisions are individualised through a neurovascular MDT and shared discussion with the patient.

  • What treatment options are there?

    Options include microsurgical resection (best for accessible low-grade AVMs), stereotactic radiosurgery such as Gamma Knife or CyberKnife (for small, deep or eloquent lesions), endovascular embolisation (as an adjunct or, for selected small lesions, as a cure), combined multimodal treatment for large or complex AVMs, and observation for selected unruptured AVMs.

  • What happens after a ruptured AVM?

    Acute care focuses on managing the intracerebral haemorrhage, controlling blood pressure, reversing anticoagulation where relevant and, in selected cases, evacuating the clot. Definitive AVM treatment is usually planned within 3 to 6 months once initial recovery has been achieved, to reduce re-rupture risk. Structured rehabilitation is a core part of the plan.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.